A Clinical Trial: In Vivo Studies on Dexamethasone Sodium Phosphate Liposomes in the Treatment of Human Aphthous Stomatitis

Farshi, F. S.; Özer, A. Y.; Tavassoli, Samaneh; Sungur, Arzu; Hıncal, A. A.

doi:10.3109/08982109609039922

Cited by 6 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DSP liposomes are separated using ultracentrifugation at 13,500 rpm for 45 minutes, and this ultracentrifugation process is repeated three times. 99 …”

Section: Discussionmentioning

confidence: 99%

“…The DSP liposomes are separated using ultracentrifugation at 13,500 rpm for 45 minutes, and this ultracentrifugation process is repeated three times. 99 The next step is the incorporation of the liposomes into the gel, called a "gelosome". Gelosomes are prepared using 1% Carbopol 940 (Kodak) in distilled water as a gel-forming agent.…”

Section: Liposomesmentioning

confidence: 99%

“…The Gelosome was made by mixing the gel and liposomes in a 1:1 ratio. 99 Liposomes display vesicular behavior when dissolved in water: the phospholipids spontaneously create a closed structure with internal environments in aqueous solutions. 59,60 The drug was entrapped in the liposomes and incorporated in the gel base containing Carbopol.…”

Section: Liposomesmentioning

confidence: 99%

“…25 This preparation was examined in patients resulting in faster ulcer healing times compared to patients treated with Kenacort Orabase Ointment. 99 Liposomal encapsulation can also be used to deposit drugs in the oral mucosal epithelium. 100 The gel will adhere to oral mucosa for a prolonged time while the drug is released from the liposome.…”

Section: Liposomesmentioning

confidence: 99%

See 3 more Smart Citations

Evolution of Drug Delivery Systems for Recurrent Aphthous Stomatitis

Suharyani¹,

Mohammed²,

Muchtaridi³

et al. 2021

DDDT

View full text Add to dashboard Cite

Recurrent aphthous stomatitis (RAS) is a disease marked by painful oral lesions on the buccal and labial mucosa or tongue. Drug delivery systems (DDS) for RAS include topical forms that manage wound healing, cover the ulcer, and relieve the associated pain. DDS targeting the oral mucosa face a major challenge, especially the short residence times in the mouth due to the effect of “saliva wash-out”, which continually removes the drug. The objective of this review is to study the development of preparation forms and delivery systems of various types and preparations that have been used for RAS management from 1965 until February 2020. There are 20 types of DDS for RAS which were discussed in 62 articles. The preparations were classified into 4 preparation forms: liquid, semi-solid, solid, and miscellaneous. In addition, the ultimate DDS for RAS preparations is the semi-solid forms (41.94%), which include 5 types of DDS are gel, paste, patch, cream, and ointment. This preparation was developed into new preparation form (11.29%), such as adhesive alginates, dentifrice, OraDisc, membranes, bioresorbable plates, pellicles, and gelosomes. Generally, the mucosal drug delivery system is the method of choice in RAS treatment because the ulcer is commonly located in the oral mucosa. In conclusion, these preparations are designed to improve drug delivery and drug activity for the treatment of RAS ulcers. Moreover, almost all of these DDS are topical preparations that use various types of mucoadhesive polymers to increase both residence time in the oral mucosa and pain relief in RAS treatment.

show abstract

“…The DSP liposomes are separated using ultracentrifugation at 13,500 rpm for 45 minutes, and this ultracentrifugation process is repeated three times. 99 …”

Section: Discussionmentioning

confidence: 99%

Section: Liposomesmentioning

confidence: 99%

Section: Liposomesmentioning

confidence: 99%

Section: Liposomesmentioning

confidence: 99%

See 2 more Smart Citations

Evolution of Drug Delivery Systems for Recurrent Aphthous Stomatitis

Suharyani¹,

Mohammed²,

Muchtaridi³

et al. 2021

DDDT

View full text Add to dashboard Cite

show abstract

“…Carbopol 940 (C 940) at the concentration of 1% (w/v) in distilled water [22] and CMCNa (carboxymethylcellulose sodium) at the concentration of 2.5% (w/v) [23] were used as gel-forming agents because of their good bioadhesive properties. For the preparation of lipogelosomes/niogelosomes, gel formulations of C 940 and CMC-Na and liposomal/niosomal DFNa were mixed in 1:1 ratio on weight basis (Table I) [8].…”

Section: Preparation Of Lipogelosomes/niogelosomesmentioning

confidence: 99%

Gamma-irradiated liposome/niosome and lipogelosome/niogelosome formulations for the treatment of rheumatoid arthritis

Türker

Özer

Kılıç

et al. 2013

IMAS

View full text Add to dashboard Cite

Treatment of rheumatoid arthritis by intraarticular administration of anti-infl ammatory drugs encapsulated in drug delivery systems, such as liposomes/niosomes and lipogelosomes/niogelosomes, prolongs the residence time of the drugs in the joint. It was therefore anticipated that liposome/niosome entrapment would enhance the effi cacy of drugs in the infl ammatory sides. Liposomes are good candidates for the local delivery of therapeutic agents, such as diclofenac sodium (DFNa), for intraarticular delivery. Drugs for parenteral delivery must be sterile, and radiation sterilization is a method recognized by pharmacopoeias to achieve sterility of drugs. However, irradiation might also aff ect the performance of drug delivery systems. One of the most critical points is irradiation dose, because certain undesirable chemical and physical changes may accompany with the treatment, especially with the traditionally applied dose of 25 kGy. The present study aims to determine the eff ects of gamma irradiation on DFNa-loaded liposomes/niosomes and lipogelosomes/niogelosomes for the treatment of rheumatoid arthritis.

show abstract